Citius Oncology Inc. Live Stock Price Today, Share Analysis and Chart

Name: Citius Oncology Inc.: Is Infosys Ltd. worth buying?
Item: Citius Oncology Inc.
Rating: 1.55325
Author: Trendlyne DVM scores

about

TenX Keane Acquisition is a newly incorporated blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

2.09 0.10 (5.03%)

66.24% Fall from 52W High

600.0K

XNAS Volume

XNAS 27 Aug, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Citius Oncology Inc. is on 29 Aug 2025 for the purpose of Citius Oncology Inc Second Quarter Earnings Results for 2025 See details

Not Eligible

Expensive Valuation

2.0 / 100

Technically Moderately Bullish

60.1 / 100

No estimates available

Citius Oncology Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Citius Oncology Inc. Live Stock Price Today, Share Analysis and Chart

TenX Keane Acquisition is a newly incorporated blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

66.24% Fall from 52W High

SWOT Analysis

Citius Oncology Inc. Live Price Chart